Surface Oncology (SURF) – Press Releases
-
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
-
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
-
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
-
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
-
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
-
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
-
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
-
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
-
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
-
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
-
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
-
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
-
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
-
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
-
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
-
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
-
Surface Oncology Appoints Carsten Brunn to Board of Directors
-
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
-
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Surface Oncology to Participate in Upcoming Investor Conferences
-
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Surface Oncology to Participate in Upcoming Investor Conferences
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
-
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
-
Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
-
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
-
Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
-
Surface Oncology Appoints Theresa Boni as General Counsel
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
-
Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
-
Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
-
Surface Oncology Appoints Denice Torres as Chair of the Board of Directors
-
Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
-
Surface Oncology Named a 2021 Top Place to Work by the Boston Globe
-
Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
-
Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG
-
Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
-
Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit
-
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021
-
Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting
-
Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021
-
Surface Oncology Appoints Denice Torres to Board of Directors
-
SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting
Back to SURF Stock Lookup
